Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRANASDAQ:ETAONASDAQ:GNCANASDAQ:SHLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K0.779,936 shsN/AETAOETAO International$2.99$1.70▼$22.00$2K1.92248,920 shs1 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/ASHLTSHL Telemedicine$2.05$2.05$1.85▼$5.10$33.61M0.1111,182 shsN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRAComera Life Sciences0.00%0.00%+100.00%0.00%-99.20%ETAOETAO International0.00%0.00%0.00%0.00%-99.54%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%+150.00%SHLTSHL Telemedicine0.00%0.00%0.00%-18.16%-61.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AETAOETAO InternationalN/AN/AN/AN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASHLTSHL TelemedicineN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRAComera Life Sciences 0.00N/AN/AN/AETAOETAO International 0.00N/AN/AN/AGNCAGenocea Biosciences 0.00N/AN/AN/ASHLTSHL Telemedicine 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞ETAOETAO International$58.89M0.00N/AN/A($16.96) per share0.00GNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00SHLTSHL Telemedicine$55.94M0.60$0.04 per share54.03$5.21 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/AETAOETAO International-$896.68MN/A0.00N/AN/AN/AN/AN/AN/AGNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/ASHLTSHL Telemedicine-$7.06MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRAComera Life SciencesN/AN/AN/AN/AN/AETAOETAO InternationalN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/ASHLTSHL TelemedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMRAComera Life SciencesN/AN/AN/AETAOETAO InternationalN/AN/AN/AGNCAGenocea Biosciences0.241.351.35SHLTSHL Telemedicine0.192.171.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRAComera Life SciencesN/AETAOETAO International0.22%GNCAGenocea Biosciences0.64%SHLTSHL Telemedicine20.11%Insider OwnershipCompanyInsider OwnershipCMRAComera Life Sciences8.90%ETAOETAO International20.80%GNCAGenocea Biosciences1.61%SHLTSHL TelemedicineN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableETAOETAO International3,6005.12 million4.06 millionNot OptionableGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableSHLTSHL Telemedicine58316.39 millionN/ANot OptionableETAO, SHLT, CMRA, and GNCA HeadlinesRecent News About These CompaniesSHL Telemedicine ADR Stock Price HistoryJune 20 at 1:03 PM | investing.comSHL Telemedicine Clarifies Voting Process for May 2025 AGMMay 20, 2025 | tipranks.comSHL Telemedicine to Delist ADRs from Nasdaq to Cut CostsMarch 11, 2025 | tipranks.comSHLT SHL Telemedicine Ltd.March 6, 2025 | seekingalpha.comSHL Telemedicine Ltd (SHLTN)January 23, 2025 | investing.comSHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News SummaryDecember 19, 2024 | benzinga.comDocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular CareDecember 18, 2024 | businesswire.comSHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comSHL Telemedicine to Appoint David Arnon as CEO of SHL TelemedicineJuly 29, 2024 | 01net.itSHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli ActivityJune 20, 2024 | businesswire.comSHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood TestMay 21, 2024 | businesswire.comSHL Telemedicine Ltd ADR - NewMay 17, 2024 | morningstar.comSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | finance.yahoo.comSHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft LaunchMay 16, 2024 | businesswire.comSHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finanznachrichten.deSHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical MilestonesApril 17, 2024 | finance.yahoo.comSHL Telemedicine Ltd. (SHLT)April 16, 2024 | finance.yahoo.comTelehealth clinical trial cuts hospital cardiac readmissions by 76%April 11, 2024 | msn.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient CareApril 11, 2024 | finance.yahoo.comImperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient CareApril 11, 2024 | businesswire.comMedia Sentiment Over TimeETAO, SHLT, CMRA, and GNCA Company DescriptionsComera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 06/18/2025Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.ETAO International NASDAQ:ETAOETAO International Co., Ltd., a digital healthcare company, provides medical care services. It develops healthcare ecosystem that consist online telemedicine, artificial intelligence, big data evaluation, online insurance, pharmacy, biotech, offline hospitals, and specialty clinics services. The company was incorporated in 2020 and is based in New York, New York.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.SHL Telemedicine NASDAQ:SHLT$2.05 0.00 (0.00%) As of 04/16/2025SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
